60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With Three Planned Trial Sites For Tafenoquine Babesiosis Study
Portfolio Pulse from Benzinga Newsdesk
60 Degrees Pharmaceuticals has signed clinical trial agreements with Yale University, Rhode Island Hospital, and Tufts Medical Center for a study on Tafenoquine for Babesiosis. Patient enrollment has begun, with interim results expected by September 2025. The market for ARAKODA® (tafenoquine) for babesiosis is approximately 400,000 patients in the U.S.
July 19, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
60 Degrees Pharmaceuticals (SXTP) has initiated clinical trials for Tafenoquine to treat Babesiosis at three major medical centers. Interim results are expected by September 2025, targeting a market of 400,000 patients in the U.S.
The initiation of clinical trials for Tafenoquine at prominent medical centers and the large potential market size are positive indicators for SXTP. The anticipation of interim results by September 2025 adds a timeline for potential milestones.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100